Wali Yasser, Shidhani Azza Al, Daar Shahina
Oman Med J. 2008 Oct;23(4):275-7.
Deferiprone is an oral chelating agent that has been recently shown to reduce cardiac siderosis, but is also known to be associated with serious side effects like agranulocytosis which can be fatal. This report is a single centre experience of 5 cases with severe agranulocytosis in amongst 144 patients (3.47%) of thalassemia major on combined chelation therapy with subcutaneous desferrioxamine and oral deferiprone which is much higher than the previous reports.
去铁酮是一种口服螯合剂，最近已显示其可减轻心脏铁沉积，但也已知其与严重副作用相关，如可能致命的粒细胞缺乏症。本报告是一项单中心经验，在144例接受皮下去铁胺和口服去铁酮联合螯合治疗的重型地中海贫血患者中，有5例发生严重粒细胞缺乏症（3.47%），这一比例远高于先前报告。
